Shire Still Pushing For $30B Baxalta Deal
Irish drugmaker Shire said Friday that it still has its eye on Baxalta, even though the U.S. rare disease biotech publicly spurned Shire's roughly $30 billion stock proposal for being too...To view the full article, register now.
Already a subscriber? Click here to view full article